Wayne Pisano Purchases 30,000 Shares of Oncolytics Biotech (TSE:ONC) Stock

Oncolytics Biotech Inc. (TSE:ONC) Director Wayne Pisano bought 30,000 shares of the business’s stock in a transaction on Thursday, February 12th. The stock was bought at an average cost of C$1.16 per share, for a total transaction of C$34,800.00. Following the purchase, the director directly owned 288,306 shares of the company’s stock, valued at approximately C$334,434.96. This trade represents a 11.61% increase in their position.

Oncolytics Biotech Price Performance

The firm has a fifty day moving average of C$14.90 and a 200 day moving average of C$13.11. Oncolytics Biotech Inc. has a 1-year low of C$0.44 and a 1-year high of C$2.08. The firm has a market capitalization of C$1.50 billion, a PE ratio of -40.27 and a beta of 0.80. The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86.

Oncolytics Biotech (TSE:ONC) last released its quarterly earnings data on Wednesday, November 12th. The company reported C($0.14) EPS for the quarter. Equities analysts anticipate that Oncolytics Biotech Inc. will post -0.41 EPS for the current fiscal year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.